Long-Term Protection of Hepatitis B Vaccine: Lessons from Alaskan Experience after 15 Years
2005; American College of Physicians; Volume: 142; Issue: 5 Linguagem: Inglês
10.7326/0003-4819-142-5-200503010-00014
ISSN1539-3704
Autores Tópico(s)Hepatitis Viruses Studies and Epidemiology
ResumoEditorials1 March 2005Long-Term Protection of Hepatitis B Vaccine: Lessons from Alaskan Experience after 15 YearsDing-Shinn Chen, MDDing-Shinn Chen, MDFrom National Taiwan University College of Medicine, Taipei 100, Taiwan.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-142-5-200503010-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Hepatitis B virus (HBV) is highly infectious and causes serious health problems worldwide. Approximately one third of the world's population has been infected, and about 400 million people have become chronic carriers (1, 2). The infection results in a wide spectrum of liver diseases, ranging from hyperacute fulminant hepatitis to refractory hepatic cirrhosis and hepatocellular carcinoma (3-5). Infection that occurs at a young age frequently results in chronic carriage of the virus. In contrast, only a small proportion of patients become chronic carriers if they contract the infection in adolescence or adulthood. Once the infection becomes chronic, HBV or part ...References1. Margolis HS. Hepatitis B virus infection. Bull World Health Organ. 1998;76 Suppl 2 152-3. [PMID: 10063701] MedlineGoogle Scholar2. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395-403. [PMID: 12127351] CrossrefMedlineGoogle Scholar3. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science. 1993;262:369-70. [PMID: 8211155] CrossrefMedlineGoogle Scholar4. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-45. [PMID: 9392700] CrossrefMedlineGoogle Scholar5. Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350:1118-29. [PMID: 15014185] CrossrefMedlineGoogle Scholar6. Chen DS. Viral hepatitis in East Asia. J Formos Med Assoc. 1996;95:6-12. [PMID: 8640098] MedlineGoogle Scholar7. Heyward WL, Bender TR, McMahon BJ, Hall DB, Francis DP, Lanier AP, et al. The control of hepatitis B virus infection with vaccine in Yupik Eskimos. Demonstration of safety, immunogenicity, and efficacy under field conditions. Am J Epidemiol. 1985;121:914-23. [PMID: 3160233] CrossrefMedlineGoogle Scholar8. Chen DS, Hsu NH, Sung JL, Hsu TC, Hsu ST, Kuo YT, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA. 1987;257:2597-603. [PMID: 3573257] CrossrefMedlineGoogle Scholar9. Harpaz R, McMahon BJ, Margolis HS, Shapiro CN, Havron D, Carpenter G, et al. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization program. J Infect Dis. 2000;181:413-8. [PMID: 10669320] CrossrefMedlineGoogle Scholar10. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001;135:796-800. [PMID: 11694104] LinkGoogle Scholar11. Kao JH, Hsu HM, Shau WY, Chang MH, Chen DS. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr. 2001;139:349-52. [PMID: 11562612] CrossrefMedlineGoogle Scholar12. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855-9. [PMID: 9197213] CrossrefMedlineGoogle Scholar13. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 1996;14:1019-27. [PMID: 8879096] CrossrefMedlineGoogle Scholar14. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19:877-85. [PMID: 11115711] CrossrefMedlineGoogle Scholar15. Liao SS, Li RC, Li H, Yang JY, Zeng XJ, Gong J, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine. 1999;17:2661-6. [PMID: 10418916] CrossrefMedlineGoogle Scholar16. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003;187:134-8. [PMID: 12508157] CrossrefMedlineGoogle Scholar17. Yuan MF, Lim WL, Chan AO, Wong DK, Sun SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clinical Gastroenterology and Hepatology. 2004;2:941-5. CrossrefMedlineGoogle Scholar18. Boxall EH, Sira JA, El-Shuhkri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis. 2004;190:1264-9. [PMID: 15346336] CrossrefMedlineGoogle Scholar19. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142:333-41. LinkGoogle Scholar20. Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13 Suppl 1 S47-9. [PMID: 7571830] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From National Taiwan University College of Medicine, Taipei 100, Taiwan.Grant Support: By the Department of Health, Taiwan, and National Science Council, Taiwan.Disclosures: None disclosed.Corresponding Author: Ding-Shinn Chen, MD, National Taiwan University College of Medicine, 1 Jen-Ai Road, Section 1, Taipei 100, Taiwan; e-mail, [email protected]mc.ntu.edu.tw. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAntibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-up Brian J. McMahon , Dana L. Bruden , Kenneth M. Petersen , Lisa R. Bulkow , Alan J. Parkinson , Omana Nainan , Marina Khristova , Carolyn Zanis , Helen Peters , and Harold S. Margolis Metrics Cited ByCross-Protection of Hepatitis B Vaccination among Different GenotypesChanges in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South KoreaStrategies to control hepatitis B: Public policy, epidemiology, vaccine and drugsSerum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of IranSafety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy infantsHepatitis B virus infection, its sequelae, and prevention by vaccinationThe worldwide impact of vaccination on the control and protection of viral hepatitis BThe response to hepatitis B vaccine: does it differ in celiac disease?Hepatitis B Response of Premature Infants after Primary and Booster Immunisation with a Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Inactivated Poliovirus/ Haemophilus Influenzae Type B VaccineHepatitis B vaccination: The key towards elimination and eradication of hepatitis BLong-term protection of hepatitis B vaccine 18 years after vaccinationPRISM hepatitis B surface antigen detection of hepatits B virus minipool nucleic acid testing yield samplesLong-term antibody persistence in children primed and boosted with a DTPw-HBV vaccine at 2, 4, 6, 18, months of ageLong-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescentsA review of the long-term protection after hepatitis A and B vaccinationHepatitis B vaccination: to boost or not to boost?Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study 1 March 2005Volume 142, Issue 5Page: 384-385KeywordsAdolescentsAntibodiesChildrenHepatitis AHepatitis BInfectious hepatitisLiver diseasesPediatric infectionsPrevention, policy, and public healthVaccines ePublished: 1 March 2005 Issue Published: 1 March 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Referência(s)